NEW YORK (GenomeWeb News) – DeCode Genetics said after the close of the market on Tuesday that it had sold to Icelandic bank NBI its auction rate securities for a price of $11 million.

Under terms of the sale, DeCode has a call option to require NBI to sell the securities back to the firm at any time prior to Dec. 31, 2009, while NBI has a put option to require DeCode to repurchase the securities following the sale of certain other DeCode assets, or if not previously repurchased, on Dec. 31, 2009.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.